USPTO, Others Say Angiomax On-Sale Bar Shouldn't Apply
The U.S. Patent and Trade Office, drug industry groups and intellectual property attorneys have urged the Federal Circuit to reverse a panel decision invalidating two of The Medicines Co.'s patents for...To view the full article, register now.
Already a subscriber? Click here to view full article